GlassScriptPhysician profile
Edward Bustamante
NPI 1427165497
$20,983.48
in general payments reported to CMS, 2019-2025
21 companies · $2,802 in 2025
The $2,802 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $199 · 2021: $778 · 2022: $3,309 · 2023: $4,129 · 2024: $9,202 · 2025: $2,802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,162 · Consulting Fee: $5,500 · Travel and Lodging: $1,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,162.46 |
| Consulting Fee | $5,500.00 |
| Travel and Lodging | $1,470.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $10,861.87 | 2022-2025 | |
| Alcon Vision LLC | $2,484.92 | 2019-2025 | Eysuvis, Rocklatan, Clareon |
| Johnson & Johnson Vision Care, INC. | $2,099.95 | 2019-2024 | Acuvue |
| Oyster Point Pharma, INC. | $1,038.54 | 2023-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $971.57 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $969.92 | 2023-2025 | Miebo, Xiidra, Alden Scleral Zenlens |
| Sight Sciences, INC. | $683.89 | 2022-2025 | Tearcare System |
| Tearlab Corp | $482.36 | 2023-2024 | Tearlab Osmolarity System, Scoutpro Osmolarity System |
| Harrow Eye, LLC | $390.05 | 2025 | Vevye |
| Dompe US, INC. | $273.82 | 2023-2025 | Oxervate |
| Rayner Intraocular Lenses Limited | $125.00 | 2024 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $109.76 | 2019 | |
| Amgen INC. | $86.91 | 2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $79.21 | 2019-2021 | |
| Glaukos Corporation | $69.13 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lombart Brothers, INC. | $54.45 | 2022 | |
| Horizon Therapeutics Plc | $49.10 | 2023 | Tepezza |
| Rxsight INC | $47.30 | 2021 | |
| Sun Pharmaceutical Industries INC. | $44.18 | 2022-2024 | |
| Thea Pharma INC. | $36.51 | 2024-2025 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $25.04 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Bustamante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.